LATIGO BIOTHERAPEUTICS
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependence or tolerability.
LATIGO BIOTHERAPEUTICS
Founded:
2018-01-01
Total Employee:
1+
Status:
Active
Total Funding:
15 M USD
Similar Organizations
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Teligene
Teligene is a drug discovery company edicating to developing innovative small-molecule drugs.
Current Employees Featured
Investors List
Corner Ventures
Corner Ventures investment in Funding Round - Latigo Biotherapeutics
More informations about "Latigo Biotherapeutics"
team - Latigo Biotherapeutics
The work we are doing at Latigo is based on unique in-house research and insights. We start with sophisticated models, human biological insights, and a discovery engine that sets us apart, …See details»
Latigo Biotherapeutics - Crunchbase Company Profile …
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain …See details»
science - Latigo Biotherapeutics
Latigo’s Phase 1 first-in-human clinical trial was designed to evaluate the safety and tolerability of single- and multiple-ascending oral doses, relative bioavailability, and food effect of LTG-001 versus placebo in healthy subjects.See details»
Latigo Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Mar 8, 2025 Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals’ pain drug approval last month, is targeting up to $150 million in a …See details»
Latigo Biotherapeutics Closes $150 Million in Series B Financing to ...
Mar 17, 2025 Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, today …See details»
Latigo raises $150M to advance pipeline through clinical trials
6 hours ago If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B …See details»
Latigo raises $150M to get non-opioid pain drugs through key tests
Mar 17, 2025 Latigo Biotherapeutics, a private drug company developing experimental pain medicines, has closed another nine-figure fundraising round. Asset manager Blue Owl Capital …See details»
Latigo Biotherapeutics Debuts with $135 Million Series …
Feb 14, 2024 Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the ...See details»
Latigo raises $150m for non-opioid painkiller push
Mar 17, 2025 Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million for drugs that it hopes will challenge Vertex ...See details»
Latigo Biotherapeutics - VentureRadar
Latigo Biotherapeutics is a biotech company focused on developing innovative non-opioid medicines for pain relief. The firm leverages human biology to create new classes of pain …See details»
Latigo Biotherapeutics - Funding, Financials, Valuation & Investors
Latigo Biotherapeutics is funded by 14 investors. Cormorant Asset Management and Foresite Capital are the most recent investors. Which investors participated in the most funding rounds?See details»
Latigo Biotherapeutics Closes $150 Million in Series B Financing to ...
Mar 17, 2025 Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board. Proceeds support advancement of company’s Na v 1.8 …See details»
Latigo saddles up with $150M to advance non-opioid pain assets
Mar 17, 2025 Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs. The round was led by Blue …See details»
Amgen vets launch Latigo Biotherapeutics to develop nonopioid …
Feb 14, 2024 The now-26-person team has developed a suite of nonopioid pain drugs. One, LTG-001, is in Phase 1 clinical trials, which are expected to end in time for the company to …See details»
Latigo Biotherapeutics Closes $150 Million in Series B Financing to ...
Mar 17, 2025 THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class …See details»
Latigo Biotherapeutics - Updates, News, Events, Signals & Triggers
Sep 9, 2021 Latigo Biotherapeutics launched with $135 million in Series A funding to develop non-opioid therapies for genetic pain targets. The company secured this funding last February …See details»
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
3 days ago Latigo Biotherapeutics granted FDA Fast Track designation for LTG-001, potential best-in-class Nav1.8 inhibitor for the non-opioid treatment of acute pain. News release. Latigo …See details»
The Week’s Biggest Funding Rounds: Nerdio Tops Slow Week Of …
3 days ago Latigo Biotherapeutics, $150M, biotech: Many patients shy away from taking opioids while many doctors are reluctant to prescribe the painkillers. Thousand Oaks, California-based …See details»
Latigo Biotherapeutics Granted FDA Fast Track Designation for …
THOUSAND OAKS, Calif., March 3, 2025 – Latigo Biotherapeutics (“Latigo”) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to LTG …See details»
Latigo Biotherapeutics Debuts with $135 Million Series A …
Feb 15, 2024 Latigo Biotherapeutics Inc. ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today …See details»